|

Cadonilimab Clinical Trials

24 actively recruiting trials across 1 location

No change since May 2026

Also known as: AK-104, AK104, Cadonilimab Injection, Cadonilimab group, Cohort 14 (cadonilimab) +1 more

Pipeline

Phase 2: 16Phase 3: 1Phase 1/2: 4

Top Sponsors

  • Akeso3
  • Sun Yat-sen University2
  • Zhongnan Hospital1
  • Zhejiang Cancer Hospital1
  • University of Texas Southwestern Medical Center1

Indications

Other23 trials

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Phase 3
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase 1/2
A Study of Ivonescimab in First-Line ES-SCLC
Phase 2
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
Phase 1/2
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Phase 2
AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
Phase 2
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
Phase 2
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Phase 1/2
Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
Phase 2
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
N/A
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Phase 2
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Phase 2
Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC
Phase 2
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Phase 2
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Phase 1/2
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
Phase 2
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
N/A
Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer
Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
Phase 2
Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer
Phase 2
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Phase 2
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Phase 2
TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study
Phase 2

Dallas, Texas1 trial

Ligufalimab and Cadonilimab in Advanced Liver Cancers

University of Texas Southwestern Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.